SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TLRY

Tilray Brands, Inc. (NASDAQ:TLRY)

CA · Delayed Price · Currency is USD
Also listed: 2HQ0.DE, TLRY.TOHealthcare · Drug Manufacturers - Specialty & Generic
$1.89-$0.18 (-8.70%)
 
Market cap
$211M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 19, 2018
Website
Market Cap$211.36M-79.1%
Revenue (ttm)$963.10M+15.9%
Net Income-$164.22M+92.4%
EPS-$1.40+93.8%
Shares Out111.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,870,379
Open$2.03
Previous Close$2.07
Day's Range$1.87 - $2.08
52-Week Range$1.87 - $15.70
Beta2.05
AnalystsHold
Price Target$10.00(+429.10%)
Earnings DateJan 11, 2027

About TLRY

Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.

Address
265 Talbot Street West, Leamington, ON, N8H 5L4, CA
Market Cap
211 million
Employees
3,595
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$69.22K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
0 Buy1 Hold0 SellAvg target $10.00 (+325.5%)

1 firm rating TLRY in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From TLRY’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-8.70%
5 Days
-21.25%
1 Month
-35.27%
6 Months
-65.38%
1 Year
-79.14%

$TLRY stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of TLRY by members of U.S. Congress

Brian Jeffrey MastHouse / RSale$50.00K – $100.00KFeb 10, 2021
Brian Jeffrey MastHouse / RSale$15.00K – $50.00KFeb 9, 2021
Brian Jeffrey MastHouse / RPurchase$15.00K – $50.00KNov 6, 2020
Brian Jeffrey MastHouse / RSale$15.00K – $50.00KFeb 4, 2019
Brian Jeffrey MastHouse / RPurchase$15.00K – $50.00KJan 18, 2019

Recently reported changes in TLRY holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TLRY's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TLRY Estimated quarterly lobbying spending

Source: U.S. Senate LDA

TLRY Revenue by Segment or Geography

$37.37MTotal
Marketing and promotion$15.74M42.11%
Selling$13.59M36.38%
Transaction costs, net$4.80M12.85%
Restructuring costs$2.45M6.55%
Litigation costs, net of recoveries$787.00K2.11%

As of: Q3 2026 (Aug 31, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New TLRY patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TLRY from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TLRY

VALTETFMG Sit Ultra Short ETF$17.21M
SILXETFMG Prime 2x Daily Junior Silver Miners ETF$14.44M
MJAmplify Alternative Harvest ETF$5.47M
HMLSFGlobal X Marijuana Life Sciences Index ETF$1.75M
THCXThe Cannabis ETF$1.25M
VHTVanguard Health Care ETF$961.88K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TLRY’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
58.63
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
72

News check: Tilray raised full-year guidance and marijuana rescheduling provide positive catalysts; mixed analysis on competitive positioning and balance sheet strength.

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$69.22K
Distinct Buyers
3

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SILXETFMG Prime 2x Daily Junior Silver Miners ETF16.37%
MJAmplify Alternative Harvest ETF7.43%
HMLSFGlobal X Marijuana Life Sciences Index ETF7.26%
HMMJ.TOGlobal X Marijuana Life Sciences Index ETF7.26%
THCXThe Cannabis ETF5.52%
BADB.A.D. ETF1.93%
LOPXDirexion Low Priced Stock ETF1.73%
YOLOAdvisorShares Pure Cannabis ETF0.91%
VALTETFMG Sit Ultra Short ETF0.52%
VHTVanguard Health Care ETF0.01%
FHLCFidelity MSCI Health Care Index ETF0.00%

Weight is the stock’s share of each fund’s holdings.